Objective: The study objectives were to determine the incidence of aminoglycoside-induced ototoxicity in institutionalized patients on intensive phase of therapy for drug-resistant Tuberculosis (DR Tb) and also to assess clinical factors which could predict the ototoxicity.
Methods: The study was a prospective analytical study among consecutive DR Tb patients who were admitted for intensive phase of therapy (of 4 months) at the DR-Tb center over a 12-month period. Patients were diagnosed as DR Tb using the Gene Xpert machine to confirm Rifampicin resistance. All eligible 70 out of 87 consenting patients were consecutively recruited into the study. Patients had baseline (admission) and serial pure tone audiometries (PTAs) performed at 4 weekly intervals until discharge after 4 months of admission. Audiometric confirmation of aminoglycoside-induced ototoxicity was done by comparing serial with baseline PTA.
Results: Among the 70 patients the male:female ratio was 1.7:1. Nine patients (12.9%) were retroviral-positive, and 16 patients (22.9%) were confirmed to have ototoxicity by audiometric criteria. The duration of treatment when ototoxicity was detected in the patients ranged 4-17 (Mean±SD; 9.4±3.4) weeks. Ototoxicity was detected in the audiometric low frequency ranges in 7 (43.8%) and at the high frequencies in 4 (25.0%) of the patients. Univariate analyses of clinical parameters found that age, underlying diabetes mellitus, deranged baseline PTAv >25dB HL, BMI on admission and retroviral status were significantly associated, while sex and previous drug regimen failure were not associated with ototoxicity. Multivariate adjusted logistic regression analyses, controlling for sex, revealed age (OR=1.068, p=0.018), BMI on admission (OR=0.673, p=0.012) and retroviral positivity (OR=8.822, p=0.014) of patients could significantly predict aminoglycoside-induced ototoxicity.
Conclusion: Incidence of aminoglycoside-induced ototoxicity in DR Tb patients was 22.9%. The clinical predictors for ototoxicity were age, BMI on admission, and co-existing retroviral infection in the patients. Clinicians should consider these factors in making choices of aminoglycosides to be used during intensive phase of treatment with second line anti-Tuberculous therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anl.2016.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiple mechanisms of aminoglycoside ototoxicity are distinguished by subcellular localization of action.
Front Neurol
November 2024
Virginia Merrill Bloedel Hearing Research Center, University of Washington, Seattle, WA, United States.
Article Synopsis
- Mechanosensory hair cells in the inner ear and lateral line of vertebrates are highly vulnerable to damage, leading to hearing and balance issues, particularly from toxic agents like aminoglycoside antibiotics and certain cancer drugs.
- Exposure to neomycin causes rapid hair cell death within an hour, while gentamicin results in delayed death, which can take up to 24 hours.
- The study identifies two different cellular mechanisms for hair cell death: acute death involves mitochondrial calcium changes and can be treated with certain antioxidants, while delayed death relates to lysosomal issues and may be mitigated by modifying endolysosomal function.
Predictive model for aminoglycoside induced ototoxicity.
Front Neurol
November 2024
Department of Surgery, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Article Synopsis
- The study developed a prediction model for aminoglycoside-induced ototoxicity (hearing loss) in a cohort of 153 adults undergoing anti-TB treatment with Streptomycin.
- Key factors influencing the risk of ototoxicity included age, cumulative dosage of Streptomycin, and baseline hearing levels, with age and dosage significantly increasing the risk.
- The model demonstrated good predictive ability, with training and validation areas under the curve indicating strong discrimination for identifying those at risk for hearing loss.
Antioxidant Therapies in the Treatment of Aminoglycoside-Induced Ototoxicity: A Meta-Analysis.
Laryngoscope
November 2024
Department of Otorhinolaryngology - Head and Neck Surgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Objective: A feared complication of aminoglycoside treatment is ototoxicity, which is theorized to be attributed to the production of aminoglycoside-induced reactive oxygen species. Previous studies using animal models have suggested that numerous therapies targeting reducing oxidative stress may prevent ototoxicity from aminoglycosides. However, few clinical studies have been conducted on these antioxidants.
View Article and Find Full Text PDFBackground: Neonates with suspected sepsis are commonly treated with gentamicin, an aminoglycoside. These antibiotics are associated with high risk of ototoxicity, including profound bilateral deafness, in people with the m.1555A>G mitochondrial genetic variant.
View Article and Find Full Text PDFHearing loss is a major health concern in our society, affecting more than 400 million people worldwide. Among the causes, aminoglycoside therapy can result in permanent hearing loss in 40% to 60% of patients receiving treatment, and despite these high numbers, no drug for preventing or treating this type of hearing loss has yet been approved by the US Food and Drug Administration. We have previously conducted high-throughput screenings of bioactive compounds, using zebrafish as our discovery platform, and identified piplartine as a potential therapeutic molecule.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!